![](/img/cover-not-exists.png)
A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention
Andrew G.C. Sutton, Victoria J. Ashton, Philip G. Campbell, Dallas J.A. Price, James A. Hall, Mark A. de BelderVolume:
57
Year:
2002
Language:
english
Pages:
7
DOI:
10.1002/ccd.10326
File:
PDF, 63 KB
english, 2002